Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.48 |
| ▸ | NPY1R | P25929 | 9/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805280 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RGNPAT | |
| SCHEMBL6046826 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RCTSG | |
| SCHEMBL6552216 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RCTSG | |
| SCHEMBL6046817 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2RCTSG | |
| SCHEMBL6046841 | 0.86 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2RCTSG | |
| SCHEMBL6554289 | 0.86 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RGNPAT | |
| SCHEMBL6664909 | 0.84 | FOLH1 (0.53) | NPY4RNPY1RNPY5RNPY2RCTSG | |
| SCHEMBL6046846 | 0.84 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RCTSG | |
| SCHEMBL6046840 | 0.83 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RCTSG | |
| SCHEMBL6802259 | 0.82 | LMNA (0.55) | NPY4RNPY1RNPY5RNPY2RGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160741-A1 | Dimeric TF antagonists | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| US-20030229018-A1 | Dimeric TF antagonist | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160741-A1 | Dimeric TF antagonists | TFPI, TFPI2, F2 | NPY4R 2562/4885NPY1R 1684/4885NPY5R 2366/4885 |
| US-20030229018-A1 | Dimeric TF antagonist | F2, TFPI, TFPI2 | NPY4R 2038/4885NPY1R 1285/4885NPY5R 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.